dangers of compounded semaglutide New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding "semaglutide" takes effect Have patients been harmed by

Stay connected Get the latest updates from MIT Technology Review Discover special offers, top stories, upcoming events, and more.

Release 323 , 240252 (2020)

The general targets for adults with type 2 diabetes are: Pre-meal glucose : 47 mmol/L Fasting plasma glucose : 57 mmol/L Post-prandial glucose (2 hours after meals): less than 8.5 mmol/L HbA1c : individualised, but typically 4853 mmol/mol (6.57.0%) for most adults These targets may be adjusted based on individual circumstances, including age, comorbidities, and hypoglycaemia awareness

Eligibility for GLP-1 therapy typically requires a body mass index (BMI) of 30 kg/m or greater, or a BMI of 27 kg/m with obesity-related conditions like type 2 diabetes or hypertension

Timely lab testing can help detect declining kidney function before it becomes advanced